Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

Caubet,Matthieu; Dobi,Erion; Pozet,Astrid; Almotlak,Hamadi; Montcuquet,Philippe; Maurina,Tristan; Mouillet,Guillaume; N'guyen,Thierry; Stein,Ulrich; Thiery‑Vuillemin,Antoine; Fiteni,Frederic

doi:10.3892/mco.2015.628

November-2015 Volume 3 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2015 Volume 3 Issue 6

Full Size Image

Article Open Access

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

Authors:
- Matthieu Caubet
- Erion Dobi
- Astrid Pozet
- Hamadi Almotlak
- Philippe Montcuquet
- Tristan Maurina
- Guillaume Mouillet
- Thierry N'guyen
- Ulrich Stein
- Antoine Thiery‑Vuillemin
- Frederic Fiteni
View Affiliations / Copyright

Affiliations: Department of Radiotherapy, University Hospital of Besançon, 25030 Besançon, France, Department of Medical Oncology, University Hospital of Besançon, 25030 Besançon, France, Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, 25030 Besançon, France

Copyright: © Caubet et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1208-1212
|
Published online on: August 31, 2015

https://doi.org/10.3892/mco.2015.628
Expand metrics +

Abstract

The combination of cisplatin or carboplatin and etoposide is the standard treatment for certain poorly differentiated neuroendocrine cancers, such as small‑cell lung cancer. The aim of this study was to assess the efficacy and tolerability of the carboplatin‑etoposide regimen in metastatic castration‑resistant prostate cancer (mCRPC). A total of 27 patients treated by carboplatin [area under the curve (AUC)=5] and etoposide (100 mg/m² intravenous infusion on days 1-3 or 75 mg orally̸day for 10 days) for mCRPC were included for analysis. The median progression‑free survival was 3.3 months [95% confidence interval (CI): 1.9‑4.2] and the median overall survival (OS) was 8.1 months (95% CI: 4.06‑12.36). The main grade 3‑4 toxicities were haematological, namely anemia (33.3%), neutropenia (25.9%) and thrombocytopenia (22.2%), whereas the most common non‑hematological toxicity was asthenia (22.2%). The efficacy, compliance and safety profile were generally similar between the oral and intravenous etoposide groups. Pretreated patients with mCRPC may benefit from the carboplatin‑etoposide regimen in terms of OS. The toxicities were acceptable, without reported treatment‑related mortality. Therefore, the oral etoposide regimen may be an viable alternative for improving the quality of life of the patients. However, this regimen requires further prospective investigation to confirm its efficacy.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Huss WJ, Gregory CW and Smith GJ: Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence. Prostate. 60:91–97. 2004. View Article : Google Scholar : PubMed/NCBI
3	Jin RJ, Wang Y, Masumori N, et al: NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64:5489–5495. 2004. View Article : Google Scholar : PubMed/NCBI
4	Di Sant'Agnese PA and Cockett AT: Neuroendocrine differentiation in prostatic malignancy. Cancer. 78:357–361. 1996. View Article : Google Scholar : PubMed/NCBI
5	Helpap B, Köllermann J and Oehler U: Neuroendocrine differentiation in prostatic carcinomas: Histogenesis, biology, clinical relevance and future therapeutical perspectives. Urol Int. 62:133–138. 1999. View Article : Google Scholar : PubMed/NCBI
6	Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
7	Loriot Y, Massard C, Gross-Goupil M, et al: Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: A prospective study evaluating also neuroendocrine features. Ann Oncol. 20:703–708. 2009. View Article : Google Scholar : PubMed/NCBI
8	Fléchon A, Pouessel D, Ferlay C, et al: Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 22:2476–2481. 2011. View Article : Google Scholar : PubMed/NCBI
9	Thiery-Vuillemin A, Dobi E, Nguyen T, et al: Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors. Anticancer Drugs. 21:958–962. 2010. View Article : Google Scholar : PubMed/NCBI
10	Eisenhauer EAI, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
11	Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
12	Aparicio A, Logothetis CJ and Maity SN: Understanding the lethal variant of prostate cancer: Power of examining extremes. Cancer Discov. 1:466–468. 2011. View Article : Google Scholar : PubMed/NCBI
13	Aparicio AM, Harzstark AL, Corn PG, et al: Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 19:3621–3630. 2013. View Article : Google Scholar : PubMed/NCBI
14	Briasoulis E, Aravantinos G, Kouvatseas G, et al: Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A Hellenic Cooperative Oncology Group clinical translational study. BMC Cancer. 13:2632013. View Article : Google Scholar : PubMed/NCBI
15	De Bono JS, Molife LR, Sonpavde G, et al: Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol. 23:1241–1249. 2012. View Article : Google Scholar : PubMed/NCBI
16	Michaelson MD, Bellmunt J, Hudes GR, et al: Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 23:1234–1240. 2012. View Article : Google Scholar : PubMed/NCBI
17	Yashi M, Nishihara D, Mizuno T, et al: Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: A prospective analysis of consecutive cases. Clin Genitourin Cancer. 12:e197–e203. 2014. View Article : Google Scholar : PubMed/NCBI
18	Scher HI, Fizazi K, Saad F, et al: AFFIRM Investigators: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
19	Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol. 31:412–419. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Carboplatin-etoposide combination chemotherapy in metastatic castration-resistant prostate cancer: A retrospective study

This article is mentioned in:

Abstract

Related Articles